Organogenesis to open $100M biotech facility in Rhode Island, will resume Dermagraft production
The company will produce its FDA-approved diabetic foot ulcer product and others at the new facility, creating over 200 full-time jobs.
Organogenesis, a regenerative medicine company focused on wound care, is planning a new biomanufacturing facility in Smithfield, Rhode Island.
The expected $100M, 122,000 square-foot facility will accommodate manufacturing, laboratory, warehouse, and distribution operations, and resume production of its FDA-approved therapy for diabetic foot ulcers, Dermagraft.
Dermagraft is a human fibroblast-derived dermal substitute (HFDS) made of a cryopreserved, absorbable, three-dimensional polyglactin mesh substrate seeded with living neonatal dermal fibroblasts.
Here’s the Science Direct article explaining the product:
https://www.sciencedirect.com/topics/engineering/dermagraft?__cf_chl_tk=pCzEII_wrmJUjQ7f65ZO1HSGuqXmYASRyje_Ii.gyL8-1747967145-1.0.1.1-WERhJ27HgBMyldIKblxczQa.I9tfl3GXjJ724V9wwhE
That’s all, short one for today ☺.
